DNA fusion vaccines enter the clinic
- PMID: 21644035
- PMCID: PMC11029487
- DOI: 10.1007/s00262-011-1042-2
DNA fusion vaccines enter the clinic
Abstract
Induction of effective immune attack on cancer cells in patients requires conversion of weak tumor antigens into strong immunogens. Our strategy employs genetic technology to create DNA vaccines containing tumor antigen sequences fused to microbial genes. The fused microbial protein engages local CD4+ T cells to provide help for anti-tumor immunity, and to reverse potential regulation. In this review, we focus on induction of CD8+ T cells able to kill target tumor cells. The DNA vaccines incorporate tumor-derived peptide sequences fused to an engineered domain of tetanus toxin. In multiple models, this design induces strong CD8+ T-cell responses, able to suppress tumor growth. For clinical relevance, we have used "humanized" mice expressing HLA-A2, successfully inducing cytolytic T-cell responses against a range of candidate human peptides. To overcome physical restriction in translating to patients, we have used electroporation. Clinical trials of patients with cancer are showing induction of responses, with preliminary indications of suppression of tumor growth and evidence for clinically manageable concomitant autoimmunity.
Figures
Similar articles
-
DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.Eur J Immunol. 2011 Aug;41(8):2447-56. doi: 10.1002/eji.201141518. Epub 2011 Jul 4. Eur J Immunol. 2011. PMID: 21604260
-
DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1.Int J Cancer. 2013 Sep 15;133(6):1400-7. doi: 10.1002/ijc.28156. Epub 2013 Apr 11. Int J Cancer. 2013. PMID: 23494538
-
Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.J Immunol. 2005 May 15;174(10):6292-8. doi: 10.4049/jimmunol.174.10.6292. J Immunol. 2005. PMID: 15879128
-
DNA fusion gene vaccines against cancer: from the laboratory to the clinic.Immunol Rev. 2004 Jun;199:156-80. doi: 10.1111/j.0105-2896.2004.00145.x. Immunol Rev. 2004. PMID: 15233733 Review.
-
DNA vaccines against cancer come of age.Curr Opin Immunol. 2010 Apr;22(2):264-70. doi: 10.1016/j.coi.2010.01.019. Epub 2010 Feb 19. Curr Opin Immunol. 2010. PMID: 20172703 Review.
Cited by
-
DNA vaccination against oncoantigens: A promise.Oncoimmunology. 2012 May 1;1(3):316-325. doi: 10.4161/onci.19127. Oncoimmunology. 2012. PMID: 22737607 Free PMC article.
-
Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.J Clin Invest. 2014 Apr;124(4):1497-511. doi: 10.1172/JCI67382. Epub 2014 Mar 18. J Clin Invest. 2014. PMID: 24642465 Free PMC article.
-
Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.Front Oncol. 2012 Nov 9;2:159. doi: 10.3389/fonc.2012.00159. eCollection 2012. Front Oncol. 2012. PMID: 23162790 Free PMC article.
-
Emerging cancer vaccines: the promise of genetic vectors.Cancers (Basel). 2011 Sep 22;3(3):3687-713. doi: 10.3390/cancers3033687. Cancers (Basel). 2011. PMID: 24212974 Free PMC article.
-
Effects of antigen-expressing immunostimulatory liposomes on chemotaxis and maturation of dendritic cells in vitro and in human skin explants.Pharm Res. 2014 Feb;31(2):516-26. doi: 10.1007/s11095-013-1179-0. Epub 2013 Sep 26. Pharm Res. 2014. PMID: 24072262
References
-
- Spies B, Hochrein H, Vabulas M, Huster K, Busch DH, Schmitz F, Heit A, Wagner H. Vaccination with plasmid DNA activates dendritic cells via toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol. 2003;171(11):5908–5912. - PubMed
-
- Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol. 2009;10(3):266–272. doi: 10.1038/ni.1702. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials